which non-bloater to use with a-bombs

[intense]

which one of these should I get to eliminate the bloat u get with anadrol at 25mg per day, or maybe the whole 50mg.

Letrozole 2.5mg/ml

or

Anastrozole 1mg/ml

and in what dosages ?

I would like to use it as a cutter, I know its hard to do, but not impossible.

I just want to fill up my muscles before my cycle ends

call me crazy.

[liftsiron]

Anastrozole works very well with with anadrol. Try .5mg ed if that doesn't wrok bump up the dose to 1mg ed.

[intense]

really you tried it before?

[jyzza]

I never had a problem w/ being bloated......when I would take someing like A-Bombs I would take it w/ Test Prop....to limit the water......I also stay away from sodium......

BTW.....I would rather use D-Bol for what you are trying to accomplish.....and if you end up going w/ Anadrol go for 50mg and keep us posted....

[intense]

I just wanted to see if I could up my strength any, plus try to blow up as much as I can before I go off cycle.

[liftsiron]

Originally posted by intense
really you tried it before?

No I haven't but I know many others who have and it worked like a charm. The bloat that one gets from A-50 is due to estrogen assocciated action by anadrol. So an anti-e is the proper action to take to prevent this.

[jyzza]

Originally posted by intense
I just wanted to see if I could up my strength any, plus try to blow up as much as I can before I go off cycle.

If thats the only reason behind it then I wouldn't take it if I were you....

Most of the gains that you will make on it will be water gains so when you come off you would crash hard loosing most of it..

Anadrol is best used in the begining of your cycle since after you stop using it your still on test and its easier for your body to maintain the newly gained weight. It also gives your body time time adjust to you gains.

[intense]

yes that makes sense, I'll just lift heavier the natural way

[house1]

If thats the only reason behind it then I wouldn't take it if I were you

agree 100 percent bro--save it for another time

[intense]

thats hard to do though!

[buyb12]

letro is better on the bloat here's why

Letrozol is femera, which is an anti-estrogen.

Femara is 10-30x more effective than Arimidex in it's ability to pass thru the cell membrane of lipid (fat) cells and inhibit the activity of aromatase -- in other words, Femara is far superior in lowering estrogen levels in fat cells. This has two benefits for BBs; (1) Estrogen 'attracts' water, so less water retention (2) an average male BB is around 10%BF, that's a lot of lipid cells with aromatase inside them, so a substantial percentage of aromatase is left untouched by Arimidex due to it's poor ability to enter lipid cellsArimidex is approximately 80% effective at inhibiting aromatase, Femara is around 95-97%, Aromasin is 98-99%

notes:
1. J Clin Endocrinol Metab 2000 Jul;85(7):2370-7
2. J Steroid Biochem Mol Biol 1997 Nov-Dec;63(4-6):261

[FKITLETSGO]

anybody with personal experience with femera?

[liftsiron]

Originally posted by FKITLETSGO
anybody with personal experience with femera?

Femera is overkill IMO, you can't reduce estrogen by 95% and expect gains also femera destroys lipid profiles where arimidex does not.

Originally posted by StonecoldNTO

Clin Cancer Res. 2003 Jan;9(1 Pt 2):468S-72S. Related Articles, Links


Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.

Buzdar AU.

Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA. abuzdar@mdanderson.org

The newer generation aromatase inhibitors (AIs) as a class show efficacy and tolerability benefits over previously established treatments in postmenopausal women with advanced breast cancer. At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) are 41-48 h, 2-4 days, and 27 h, respectively. Time to steady-state plasma levels is 7 days for both anastrozole and exemestane and 60 days for letrozole. Androgenic side effects have only been reported with exemestane. Anastrozole treatment has no impact on plasma lipid levels, whereas both letrozole and exemestane have an unfavorable effect. From indirect comparisons, anastrozole shows the highest degree of selectivity compared with letrozole and exemestane, in terms of a lack of effect on adrenosteroidogenesis. To date, there are no data suggesting any major differences in clinical efficacy between the newer generation AIs anastrozole and letrozole. Based on the observed pharmacological profiles, however, it cannot be assumed that the AIs will display the same tolerability and safety profiles when given for extended periods of time in the adjuvant setting. The effects of anastrozole, letrozole, and exemestane are being investigated in the adjuvant setting, and these data will elucidate the possible long-term consequences of the pharmacological effects reported after short-term exposure.

-----------------------------

Cancer. 2002 Nov 1;95(9):2006-16. Related Articles, Links


An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.

Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM.

Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. abuzdar@mdanderson.org

BACKGROUND: The newer generation, nonsteroidal aromatase inhibitors (AIs) anastrozole and letrozole have shown superior efficacy compared with tamoxifen as first-line treatments and compared with megestrol acetate as second-line therapy in postmenopausal women with advanced breast carcinoma. In an open-label, Phase II trial, it was reported that exemestane showed numerical superiority compared with tamoxifen for objective response and clinical benefit. Because these agents ultimately may be administered for periods of up to 5 years in the adjuvant setting, it is of increasing importance to assess their tolerability and pharmacologic profiles. METHODS: In the absence of data from direct clinical comparisons, the published literature was reviewed for the clinical pharmacology, pharmacokinetic characteristics, and selectivity profiles of anastrozole, letrozole, and exemestane. RESULTS: At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) were 41-48 hours, 2-4 days, and 27 hours, respectively. The time to steady-state plasma levels was 7 days for both anastrozole and exemestane and 60 days for letrozole. Androgenic side effects have been reported only with exemestane. Anastrozole treatment had no impact on plasma lipid levels, whereas both letrozole and exemestane had an unfavorable effect on plasma lipid levels. In indirect comparisons, anastrozole showed the highest degree of selectivity compared with letrozole and exemestane in terms of a lack of effect on adrenosteroidogenesis. CONCLUSIONS: All three AIs demonstrated clinical efficacy over preexisting treatments. However, there were differences in terms of pharmacokinetics and effects on lipid levels and adrenosteroidogenesis. The long-term clinical significance of these differences remains to be elucidated. Copyright 2002 American Cancer Society.

[jyzza]

Good post liftsiron